Korean J Pediatr Hematol Oncol.
2004 Apr;11(1):92-96.
Defibrotide Treatment for Hepatic Veno-occlusive Disease after Umbilical Cord Blood Transplantation
- Affiliations
-
- 1Department of Pediatrics, Chonnam National University Medical School, Gwangju, Korea. hoonkook@chonnam.ac.kr
- 2Department of Pediatrics, Choongbook National University Medical School, Cheong-ju, Korea.
Abstract
- Veno-occlusive disease (VOD) of the liver is a life-threatening complication occurring early after blood or bone marrow transplantation (BMT). Effective treatment has not been established in case of severe forms of VOD. Defibrotide, a single-stranded polydeoxyribonucleotide, has been used on a compassionate basis in recent clinical trials with promising results. We report here with the first Korean experience of using defibrotide for the treatment of hepatic VOD occurring after unrelated umbilical cord blood transplant in a 2-year-old child with acute lymphoblastic leukemia. Defibrotide was administered for 23 days without any significant side effects with resolution of signs and symptoms of VOD.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Severe Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with Defibrotide
- Hepatic veno-occlusive disease resulting in tacrolimus toxicity after allogeneic hematopoietic stem cell transplantation
- Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea
- Hepatic Veno-occlusive Disease after Bone Marrow Transplantation in Leukemic Patients: Two Cases Proven by Laparoscopic Liver Biopsy
- Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation
